Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Gastric cancer (GC) is a common cause of cancer-related death worldwide. As a result of the lack of reliable diagnostic or prognostic biomarkers for GC, patient prognosis is still poor. Therefore, there is an urgent need for studies examining the underlying pathogenesis of GC in order to find effective biomarkers.
LRRN1
(leucine-rich repeat neuronal protein-1) is a type I transmembrane protein that plays an important role in the process of nerve development and regeneration. However, its role in cancer, especially in GC, remains unclear. In the present study, we found that
LRRN1
expression is upregulated in GC tissues and that high
LRRN1
expression is associated with poor prognosis. siRNA and shRNA-mediated knockdowns of
LRRN1
expression promoted GC cell apoptosis and activation of the Fas/FasL pathway.
LRRN1
knockdown also resulted in upregulation of JUN, a subunit of the
transcription factor AP-1
(activator protein-1). This suggests that
LRRN1
suppresses GC cell apoptosis by downregulating AP-1, resulting in inhibition of the Fas/FasL pathway. These results confirm that
LRRN1
plays a significant role in GC pathogenesis. Moreover,
LRRN1
may be a potential prognostic biomarker and therapeutic target for GC.
...
PMID:Leucine-rich repeat neuronal protein-1 suppresses apoptosis of gastric cancer cells through regulation of Fas/FasL. 3108 25